Related Experiment Video
Updated: Sep 2, 2025
05:08
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
Published on: October 3, 2019
11.3K
Epi-Drugs in Heart Failure.
Era Gorica1,2, Shafeeq A Mohammed1, Samuele Ambrosini1
1Center for Molecular Cardiology, University of Zürich, Schlieren, Switzerland.
Frontiers in Cardiovascular Medicine
|August 1, 2022
Summary
Epigenetic therapies offer new hope for treating heart failure, particularly HFpEF. Research into chromatin biology and non-coding RNAs is paving the way for personalized epigenetic drugs to restore healthy heart function.
Area of Science:
- Cardiovascular Biology
- Epigenetics
- Pharmacology
Background:
- Epigenetic mechanisms, including DNA methylation and non-coding RNAs (ncRNAs), play a crucial role in regulating gene expression.
- Dysregulation of epigenetic networks underlies pathological features in heart failure, such as left ventricular hypertrophy and fibrosis.
- Current treatments for heart failure with preserved ejection fraction (HFpEF) are limited, highlighting the need for novel therapeutic strategies.
Purpose of the Study:
- To review the timeline of epigenetic drug discovery and development for cardiovascular diseases.
- To highlight the emerging role of epigenetic therapies in managing heart failure, especially HFpEF.
- To discuss the potential of epigenetics in developing personalized medicine approaches for heart conditions.
Main Methods:
- Review of existing literature on epigenetic mechanisms in heart failure.
- Analysis of epigenetic drug development and clinical applications.
- Exploration of therapeutic targets within epigenetic pathways.
Main Results:
- Epigenetic modifications are implicated in key pathological processes of heart failure.
- Epigenetic drugs show promise in modulating transcriptional programs relevant to cardiovascular diseases.
- The development of more selective epigenetic compounds is crucial for clinical translation.
Conclusions:
- Epigenetic therapies represent a promising frontier for treating heart failure, offering potential for personalized medicine.
- Targeting epigenetic signals can address underlying molecular mechanisms in HFpEF where therapeutic options are scarce.
- Further research and development of selective epi-drugs are needed to fully realize their clinical potential in cardiovascular medicine.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
497
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
497
01:22Heart Failure Drugs: Diuretics
472
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
472
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:26Heart Failure Drugs: Inotropic Agents
704
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
704
01:22Heart Failure Drugs: β-Blockers
424
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
424
01:22Heart Failure VI: Adjunct Therapies
25
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25